PHASE I  

  

Healthy Adults  
2025	ENSHO THERAPEUTICS: A Phase 1 Study to Evaluate the Phannacokinetics, Safety, and Tolerability of in Healthy Participants
2025	BMS: A Phase 1, 4-part, Open-label Study to Evaluate the Effects of XXX Phenotypes on the Pharmacokinetics of Xanomeline Following XXX Administration in Healthy Adults Participants

2025	PFIZER: A Phase 1, Ranodmized, Double-Blind, Third-Party-Unblinded Study To Evaluate The Safety And Tolerability Of A Vaccine Against E Coli In Healthy Adults

2025	ABBVIE: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of XXX in Healthy Adult Western and Asian Subjects

2025	ABBVIE: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXX Following Subcutaneous Administration with On-Body Injector

2025	GENFIT: A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety, and Tolerability of XXX in Healthy Subjects


2025	ABBVIE: A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of XXXX  

  

2025	BMS: A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of XXXX, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants  

  

2025	CELLARITY: A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Volunteers and Participants with Sickle Cell Disease  

  

2025	ELI LILLY: A Single-Ascending Dose Study to Evaluate the  Safety and Pharmacokinetics of XXXX in Healthy Participants.  

  

   

  

2025	ELI LILLY AND COMPANY: A single-ascending and multiple-ascending dose study of XXXX in healthy participants, participants with obesity and hypertension, and participants with decreased estimated glomerular filtration rate.  

  

2025	ELI LILLY AND COMPANY: A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of XXXX (XXX) in Healthy Participants  

  

2025	GILEAD: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Volunteers and to Evaluate the Effect of Food and Acid-Reducing Agents on XXXX Pharmacokinetics  

  

2025	GILEAD: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX, and the Effect of Food and Acid-Reducing Agents on the Pharmacokinetics and Pharmacodynamics of XXXX  

  

2025	VISTERRA: A phase 1, randomized, placebo-controlled, double blind, multiple ascending dose trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of XXXX in healthy participants.  

  

   

  

2025	MERCK: A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of XXXX (XXXX) Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation Cardiovascular  

  

2025	GENENTECH: A Phase 1, Randomized, Two-Part, Parallel-Group Study to Assess the Bioequivalence of Subcutaneously Administered XXXX Via Different Subcutaneous Delivery Platforms in Healthy Male Subjects  

  

2025	VIATRIS INNOVATION GmbH:  Single-center, double-blind trial to assess the pharmacokinetics, the pharmacodynamics, and the tolerability of a single 16 mg dose of XXXX (XXXX) in healthy Japanese and Caucasian participants  

  

2024	ABBVIE: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Formulations of XXXX Following Subcutaneous Administration with Prefilled Syringes  

  

2024	ABBVIE: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Western, Japanese, and Han Chinese Subjects  

  

2024	ABBVIE: An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects  

  

2024	ALLIANTHERA: A Phase I, Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral XXXX in Healthy Volunteers  

  

2024	BMS: Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of XXXX with Immediate-Release XXXX Chloride versus XXXX in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of XXXX with Immediate-Release XXXX Chloride in Healthy Adult Participants (Part 2)  

  

2024	BMS: An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of XXXX To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants  

  

2024	ECCOGENE: A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of XXXX on the Single Dose Pharmacokinetics of XXXX, XXXX, XXXX and XXXX in Healthy Participants  

  

2024	ELI LILLY AND COMPANY: A Bioequivalence Study of Subcutaneous Injections of Citrate-Free XXXX solution Using a 1mL Autoinjector and an Investigational 2mL Autoinjector in Healthy Participants  

  

2024	GILEAD: A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Oral XXXX in Healthy Japanese Participants  

  

2024	GILEAD: A Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Different Formulations of Subcutaneous and/or Intramuscular XXXX in Healthy Participants  

  

2024	PFIZER: A Two-Part Phase 1, Open- Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of XXXX Following Oral Administration and the Effects of Steady-State XXXX on the Pharmacokinetics of Single Oral Dose of XXXX and XXXX in Otherwise Healthy Adult Participants with Overweight or Obesity  

  

2024	UCB: A Single-Center, Randomized, Investigator- And Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, And Pharmacokinetics After a Single Dose of XXXX in Healthy Chinese and Japanese Participants  

  

2023	ABBVIE: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXXX Vials Manufactured by Two Different Processes  

  

2023	ONENESS: A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of XXXX for Single Subcutaneous Administration in Healthy Adults                

  

2023	PFIZER: A Phase 1, Open-Label, Randomized Study with a 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose P150harmacokinetics Between Immediate and Modified Release Formulations of XXXX Administered Orally to Healthy Adult Participants    

  

2023	VIATRIS: A Randomized, Double-Blind, 3-arm Parallel Phase 1 Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX Following a Single Dose of 420 mg Intravenous Infusion Compared to the EU and US Marketed Drug Product (Perjeta®) in Healthy Male Volunteers             

  

2022	ABBVIE: A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of XXXX 150 mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90 mg/mL Formulation in the 90 mg Prefilled Syringe   

  

2022	BRISTOL-MYERS QUIBB: An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of XXXX at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (XXXX XXXX/XXXX) in Healthy Female Participants     

  

2022	ABBVIE: Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of XXXX, XXXX and XXXX, and Potential of XXXX for CYP3A Induction in Healthy Volunteers     

  

2022	EISAI: An Open-Label, Parallel-Group, Randomized Study to Demonstrate the Bioequivalence of the Subcutaneous Formulation of XXXX Supplied in Vials and a Single Use Auto-Injector  

  

2022	BRISTOL-MYERS SQUIBB: A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of XXXX (also known as XXXX and XXXX) Administered using Autoinjector versus using Prefilled Syringe, and to Evaluate the Pharmacokinetics of XXXX When Administered by Autoinjector at Different Injection Sites, in Healthy Participants.  

  

2022	BRAINTREE: Examination of Gastric Mucosal Abnormalities Before and After Bowel Preparation   

  

2022	PFIZER: A Phase 1, Open-Label, Randomized, Single Dose, 2-Way Crossover Study Assessing Pharmacokinetic Comparability Of Two XXXX Presentations, On-Body Injector And Prefilled Syringe, In Healthy Participants    

  

2021	AMGEN, INC.: An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the Comparability of a Single Subcutaneous Dose of XXXX When Delivered Manually From A Prefilled Syringe Versus Delivered by an Autoinjector.    

  

2021	BIOGEN: A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of XXXX (XXXX) Compared to a Single, Weight-Based Intravenous Dose in Healthy Volunteers.    

  

2021	BIOGEN: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adults.    

  

2021	CELGENE INTERNATIONAL: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled (XXXX), Comparator-Controlled (XXXX), Multiple-Dose, Parallel-Group Study to Investigate the Pressor Effect of Oral XXXX During XXXX Treatment in Healthy Adult Subjects.   

  

2021	ELI LILLY & COMPANY: A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants.      

  

2021	GILEAD SCIENCES, INC.: A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between XXXX (XXX) and XXXX (XXX).  

  

2021	GLAXOSMITHKLINE: A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study To Compare Formulations Produced By Two Methods Of Manufacture For Bioequivalence And Dissolution In Healthy Adult Volunteers              

  

2020	ABBVIE: A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of XXXX in Healthy Subjects  

  

2020	ASTRAZENECA: A Phase I, Open-label, Randomized, Single-dose Study of XXXX in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (XXXX) on XXXX Capsule when Administered Orally with COCA-COLA.    

  

   

  

2020	GENERON CORP.: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Male Subjects.    

  

   

  

2020	GLAXOSMITHKLINE: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX Administered Subcutaneously in Healthy Participants   

  

   

  

2020	POLPHARMA: A Phase 1, Single Dose, Randomized, Double-Blind Parallel Group Study to Compare the Pharmacokinetics and Pharmacodynamics of XXXX with XXXX in Healthy Subjects.  

  

  

  

2019 		BMS:A phase I ,A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and	Immunologic Effects of XXXXX, and a Relative Bioavailability Study in Healthy Participants     

  

  

  

Cardiovascular  

  

2023	BRISTOL-MYERS SQUIBB: A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Precious MyoKardia Formulation of XXXX and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants     

  

2023	BRISTOL-MYERS SQUIBB: An Open-label, Randomized, Single-dose, Three-way Crossover Study to Establish Bioequivalence of 5 mg XXXX Capsule 1 and 5 × 1 mg XXXX Capsule 2 to 5 mg XXXX Capsule 2 in Healthy Participants    

  

2023	PFIZER: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of XXXX in Healthy Adult Participants and Repeat Doses in Participants with Pulmonary Arterial Hypertension     

  

2021	AMGEN, INC.: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG XXXX in Subjects with Obesity.    

  

2021	BRISTOL-MYERS SQUIBB RESEARCH AND DEVELOPMENT: An Open-label, Randomized, Two-Period Cross-over Study to Investigate the Relative Bioavailability of XXXX in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration with Auto-injector Versus Pre-filled Syringe.    

  

  

  

Dermatology  

  

2024		ELI LILLY AND COMPANY: a Phase I, Multicenter, Randomized, Placebo-		Controlled, Double-Blind, Single-Ascending Dose Study 	of XXXX in 	Healthy Participants, a Multiple-Ascending Dose Study of 	XXXX in Patients 		with Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the 		Safety and Tolerability of Prednisone in Health Participants.  

  

2024	PFIZER: A Phase 1, First in Human, Randomized, Double-Blind, Sponsor open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and Participants with Moderate to Severe Atopic Dermatitis  

  

2023	ABBIVE: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXXX in Vials Manufactured by Two Different Processes.    

  

2020	PFIZER: A Phase 1 First In Human, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and Participants with Atopic Dermatitis.  

  

2019 		ABBVIE: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose 		Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXXX in Healthy 		Volunteers and in Subjects with Chronic Plaque Psoriasis.    

  

2019 		ABBVIE: A Phase 2-4 Study, Multicenter, Randomized, Double-Blind, 		Placebo-Controlled Study to Assess the Safety and Efficacy of the XXXXX Using a 		New Formulation for the Treatment of Adult Subjects with Moderate to Severe 		Plaque Psoriasis.  

  

  

  

Endocrinology/Metabolic  

2025	KAILERA: A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of a Low Fat Meal and Evening Dosing on the Pharmacokinetics and Tolerability of XXX in Healthy Participants Living with Obesity or Overweight

2025	AMGEN INC.: A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of XXXX (XXX) as Two Subcutaneous Presentations in Participants Living with Overweight or Obesity

2025	AMGEN: A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of XXXX (XXX) as Two Subcutaneous Presentations in Participants Living with Overweight or Obesity  


2025	ELI LILLYANDCOMPANY: A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of XXXX, and Single and Multiple Weekly Subcutaneous Doses of XXXX with XXXX in Participants with Overweight or Obesity  

  

2025	PFIZER: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Pharmacokinetic Interactions Between XXXX and XXX in Otherwise Healthy Adult Participants with Overweight or Obesity          

  

2024	AMGEN: A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of XXXX Administered Subcutaneously in Subjects with Overweight or Obesity  

  

2024	AMGEN:  A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Participants with Obesity  

  

2024	AMGEN: A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of XXXX Administered Using One of Three Drug Products in Participants Living with Overweight or Obesity  

  

2024	ELI LILLY: A Multiple-Dose Study to Investigate the Bioequivalence of XXXX (XXX) Capsules and XXXX Tablets in Participants with Obesity or Overweight who are Otherwise Healthy  

  

2024	ELI LILLY AND COMPANY: A Single- and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants with Type 2 Diabetes Mellitus  

  

2024	PFIZER: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus  

  

2023	GASHERBRUM: A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Adult Overweight or Obese Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus on Metformin    

  

2023	REGENERON: A randomized, double-blind study of the efficacy and Safety of XXXX, with or without XXXX, in Addition to Semaglutide in patients with obesity      

  

2022	ECCOGENE: A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and in Patients with Type 2 Diabetes Mellitus   

  

2022	ELI LILLY & CO: A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX Alone and in Combination with XXXX in Patients with Type 2 Diabetes  

  

2020	AMGEN, INC.: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Obesity.    

  

   

  

2020	ELI LILLY & CO: A Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of XXXX in Patients with Type 2 Diabetes Mellitus.   

  

   

  

2020	ELI LILLY & CO: A Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Patients with Type 2 Diabetes Mellitus   

  

2020	PFIZER: Phase 1, Open-Label, Fixed Sequence Study to Evaluate the Effect of Two Dose Levels of XXXX on the Pharmacokinetics of Single Oral Doses of XXXX and XXXX, Administered Separately in Adult Participants with Obesity.    

  

   

  

2020	PFIZER: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus.  

  

2019		APPLIED: A Phase 1-2, Dose-Escalating, 4-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of XXXXX in Healthy Adult Subjects and Adult Subjects with Classic Galactosemia (CG)     

  

2019 		NOVO NORDISK: A Trial Comparing NNC0148-0287 C (insulin 287) Versus 	Insulin Glargine U100, Both in Combination with Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, In Insulin-Naïve Subjects with Type 2 Diabetes Mellitus.    

  

   

  

   

  

2019	 NOVO NORDISK: Investigation of safety and efficacy of XXXXX for weight management –a dose finding trial      

  

   

  

2019 		PEGBIO: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-Weekly Subcutaneous Doses of XXXXX to Patients with Type 2 Diabetes Metformin Monotherapy.   

  

   

  

2019 		SELECTA BIOSCIENCES: An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of XXXXX in Subjects with Symptomatic Gout and Elevated Blood Uric 	Acid (SEL-212/201)    

  

   

  

2019		SHANTON XXXX: A Multicenter, Randomized, Double-blind, Placebo controlled, Dose escalation study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of XXXXX in Gout Patients with Hyperuricemia.    

  

   

  

2019		SHANTON: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, 	Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXXX in Gout Patients with Hyperuricemia.  

  

  

  

Ethnic Bridging  

  

2025	IMMUNOVANT SCIENCES GmbH: A Phase 1, Open-Label Study to Access Pharmacodynamics, Safety and Tolerability of XXXX Following a Single Subcutaneous Dose in Healthy Participants of Japanese Origin.  

  

2024		BRISTOLMYERSQUIBB: A Phase 1, Randomized, Double-blind, 			Placebo-controlled, Multiple Ascending Dose Study to evaluate the 			Safety, Tolerability, Pharmacodynamics of Orally Administered XXXX in 		Health Participants, Healthy Elderly Participants, and Healthy Participants 		of Japanese Ethnicity  

  

2024	ELI LILLY AND COMPANY: Single-and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX Following Oral Dosing in Healthy Participants  

  

2023	ABBVIE: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects   

  

2023	ABBVIE: An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects   

  

2023	BRISTOL-MYERS SQUIBB: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Caucasian Participants        

  

2023	ELI LILLY & CO: A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics with Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of XXXX in Healthy Participants, Including First-Generation Japanese Participants    

  

2023	GASHERBRUM: A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Japanese and Non-Japanese Healthy Volunteers        

  

2023	GILEAD : A Phase 1 Single-Dose Study to Evaluate the Pharmacokinetics and Tolerability of XXXX (XXXX) in Healthy Japanese and White Participants       

  

2023	IDORSIA: A Single-Center, Open-Label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 x 10 mg tablets and 2 x 25 mg tablets of XXXX in Healthy Male and Female Japanese Participants     

  

2023	VENTYX: A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXX Following an Oral Administration in Healthy Japanese and Caucasian Subjects    

  

2022	ABBVIE: This is a Phase 1, double-blind, sequential, placebo-controlled, single center, randomized study in which healthy Japanese subjects will receive a single XXXX dose or placebo. Healthy Han Chinese subjects will also receive a single XXXX dose, but no Han Chinese subjects will receive placebo, and there will be no randomization of Han Chinese subjects. A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult, Japanese, and Han Chinese Subjects  

  

2022	BIOGEN: An Open-Label, Parallel-Group, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of XXXX In Healthy Adult Japanese, Chinese, And Caucasian Participants  

  

2022	BIOGEN: A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of XXXX (XXXX) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers     

  

2022	BRISTOL-MYERS SQUIBB: A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants of Japanese Descent   

  

2022	BRISTOL-MYERS SQUIBB: A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of XXXX in Healthy Adult Japanese Participants    

  

2022	BRISTOL-MYERS SQUIBB: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food Effects on the Relative Bioavailability of XXXX / XXXX     

  

2022	CINCOR: A Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Japanese and Caucasian Subjects     

  

2022	GILEAD SCIENCES: A Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese Participants     

  

2022	INTRA-CELLULAR: An Open-Label, Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Japanese and Healthy Caucasian Subjects     

  

2022	SUMITOVANT: A Phase I Randomized, Double-Blind, Multi-Part, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Dose of XXXX Alone and Co-administered with Meropenem in Healthy Subjects      

  

2021	BIOGEN: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Non-Japanese Participants.     

  

2021	ELI LILLY & COMPANY: A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Non-Japanese and Japanese Participants.  

  

2021	GLAXOSMITHKLINE: A Phase I, Single-Blind, Randomized, Single-Dose Clinical Pharmacology Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of XXXX Vs Placebo By Intravenous Or Intramuscular Administration In Healthy Japanese And Caucasian Participants.  

  

2021	QED THERAPEUTICS: A Phase 1, An Open-Label, Multiple Dose, Ethnic Sensitivity Study of XXXX (XXXX) XXXX mg in Japanese vs. Caucasian Healthy Subjects.  

  

2021	TEVA: An Open-Label, Randomized, Phase 1 Subcutaneous Single-Dose Study to Assess the Pharmacokinetics, Safety, Immunogenicity, and Tolerability of XXXX (Doses up to XXXX mg) in Healthy Adult Japanese and Caucasian Subjects.    

  

2021	UCB BIOPHARMA: A Placebo-Controlled, Double-Blind, Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics (PK) of XXXX XXXX in Healthy Japanese, Chinese, and Caucasian Participants     

  

2020	BIOGEN: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX XXXX (XXXX) in Healthy Male Japanese and Caucasian Study Participants.   

  

   

  

2020	CELLTRION: A Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of XXXX and EU-Approved XXXX in Healthy Japanese Male Subjects     

  

   

  

2020	CSL BEHRING: A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous and Intravenous XXXX in Healthy Adult Japanese and Caucasian Subjects.    

  

2019		AMGEN: A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXXX in Japanese Subjects with 			Elevated Plasma Lipoprotein(a). .   

  

2019 		ANAPTYSBIO: A Phase 1, Single-Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of XXXXX in Healthy Japanese and Caucasian Subjects.  

  

2019 		CELGENE: A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of XXXXX in Healthy Japanese and 	Caucasian Adult Subjects.   

  

   

  

2019 		ESPERION: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending and Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of XXXXX Acid in Healthy Japanese and Additional East Asian Ethnicity Cohorts.   

  

   

  

2019 		IDORSIA: A Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics after Single-Dose Administration of 4mg XXXXX in Healthy 		Japanese and Caucasian Subjects.   

  

   

  

2019		PFIZER: A Phase 1, Randomized, Double-blind, Placebo-Controlled Study 	to Evaluate The Safety, Tolerability and Pharmacokinetics of Single-Dose Subcutaneous Administration of XXXXX to Healthy Adult Japanese Participants.  

  

  

  

Hepatology  

  

2023	PFIZER: A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX in Adult Participants with Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment     

  

Gastroenterology  

  

2024	ECCOGENE: An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Table Formulation (F2) of XXXX and Food Effects on F1 and F2 XXXX in Healthy Participants  

  

2023	PFIZER: A Phase 1B Open-Label/Phase 2 Double-Blind Placebo-Controlled Study for Pharmacodynamic Activity, Pharmacokinetics, Safety and Tolerability of XXXX in Patients with Celiac Disease         

  

2020	KANYOS: A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.     

  

2020	PVP BIOLOGICS: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease  

  

2019		GOSSAMER: A Phase 1a, Randomized, Double-Blind, Placebo-					Controlled, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, 		and Pharmacodynamic Effects of Tablet Formulations of XXXXX in Healthy Male and 		Female Volunteers.   

  

2019 		PHATHOM: A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate 	the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to	Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive 	Esophagitis.    

  

   

  

2019	PHATHOM: A Phase 3, Randomized, Multicenter Study to Evaluate the 				Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection.   

  

   

  

2019 PVP XXXX: A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics 		of PVP001 and PVP002 in Healthy Adult volunteers and Adults with Celiac Disease and to Asses the Gluten Degradation Activity of PVP001 and PVP002 in Healthy Adult Volunteers (PVP-102-01)    

  

  

  

Immunology  

  

2024	GILEAD: A Phase 1a Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XXXX for Injection in Healthy Participants  

  

2023	BIOGEN: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adult Participants  

  

2023	BRISTOL-MYERS SQUIBB: A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of XXXX in Healthy Adult Participants (Immunomodulator)  

  

2023	BIOGEN: A Phase 1, randomized, Double-Blind, Crossover Study to Evaluate the Bioequivalence of XXXX (XXXX, XXXX) Manufactured at Biogen Oral Solid Dose (OSD) in Healthy Adult Participants     

  

Neurology  

  

2024	ADEL, INC. AND OSCOTEC INC.: First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of XXXX in Healthy Participants and in Participants with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer  

  

2023	BRISTOL-MYERS SQUIBB: A Phase 1, Open-label, Randomized, Parallel-group, Single dose Study to Assess the Relative Bioavailability of a New XXXX Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants    

  

2021	EISAI, INC.: An Open-Label, Parallel-Group, Randomized Study to Evaluate the Absolute Bioavailability of a Single Dose Subcutaneous Administration of XXXX in Healthy Subjects.       

  

  

  

Psychiatry  

  

2023	ABBVIE: Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of XXXX in Healthy Adult Subjects     

  

Vaccine  

  

2025	GILEAD: Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of XXXX in Healthy Participants and Participants with Chronic Hepatitis Delta  

     



2025	PFIZER: A Phase 1/2 Randomized, Double-Blinded Study to Evaluate the Safety, Tolerability, And Immunogenicity of Modified RNA Vaccine Candidates Against Influenza and Covid-19 In Healthy Individuals  

  

2024	ELI-LILLY&CO: A Phase 1, randomized, placebo-controlled, investigator and participant blinded, single ascending dose and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics of XXXX in healthy participants.  

  

2024	MERCK SHARP&DOHME: Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX in Healthy Adults.  

  

2024	PUBLIC HEALTH VACCINES: A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of XXXX, a Nipah Virus Vaccine Candidate (XXXX) in Healthy Adults  

  

2024	PFIZER: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX Vaccines Against Influenza in Healthy Adults  

  

2023	PFIZER: A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a XXXX Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults        

  

2021	FLUGEN, INC.: A Phase 1b, Clinical Study to Investigate the Safety and Immunogenicity of the XXXX (A/Singapore/XXXX) XXXX Monovalent Influenza Vaccine in Adults Ages 50 To 85 Years Old.  

  

  

  

Women’s Health  

  

2023	PFIZER: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX on the Pharmacokinetics of Single-Dose XXXX, XXXX and an Oral Contraceptive, and the Effect of Steady-State XXXX on the Pharmacokinetics of Single-Dose XXXX, in Obese Adult Female Participants     

  

2021	GILEAD SCIENCES, INC.: A Phase 1 Drug Interaction Study Evaluating the Effect of XXXX on the Pharmacokinetics of the Combined Hormonal Oral Contraceptive XXXX/XXXX in Healthy Female Subjects.  

  

2021	PFIZER: A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX On the Pharmacokinetics of Single Oral Doses of XXXX and XXXX In Healthy Adults and An Oral Contraceptive In Healthy Post-Menopausal Female.  

  

2020	KANYOS: A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.     

  

2020	PVP BIOLOGICS: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease  

  

2020	MILLENDO: A Phase 1 Single Ascending Dose Study in Healthy Men, A Food-Effect Study in Postmenopausal Women, and A Multiple Ascending Dose Study in Postmenopausal Women with Vasomotor Symptoms (VMS) to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX.  

  

  

  

Other Indication  

  

2024	METSERA: A Phase 1/2 Randomized Placebo-Controlled Double-Blind Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Doses of XXXX in Adult Participants with Obesity or Overweight but Otherwise Healthy  

  

2024	PFIZER: A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two XXXX Film-Coated Tablet Formulations Administered as 150 MG Under Fasted Conditions  

  

2023	GILEAD: A Phase 1 Study to Evaluate Transporter and Cytochrome XXXX-Mediated Drug-Drug Interactions Between XXXX and XXXX, XXXX, and XXXX in Healthy Participants    

  

2023	VISTERRA: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose, First-in-Human, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Male and Female Participants     

  

2022	CSL BEHRING: A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacokinetic Properties of XXXX Administered by Subcutaneous Autoinjector to Prefilled Syringe in Healthy Adult Subjects     

  

2021	ELI LILLY & COMPANY: An Open-Label, Randomized Study To Evaluate The Bioequivalence Of XXXX Tablet And Capsule Formulations  

  

2019	DURECT: A Randomized, Open-Label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of XXXXX in Patients with Non-Alcoholic Steatohepatitis (NASH).   

  

2019	INTERVEXION: STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy.       

  

  

  

PHASE II – IV  

  

Dermatology  

  

2023	AMGEN: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind, Study to Assess the Efficacy, Safety and Tolerability of XXXX (XXXX) Monotherapy in Adult Subjects with Moderate-to-severe Atopic Dermatitis (AD).   

  

Endocrinology/Metabolic  

2025	VERDIVA: A Randomized, Double-Blind, Placebo-Controlled Phase 2B Study of Weekly Oral Ecnoglutide (XXX) in Participants Who Have Obesity or Overweight with Weight-Related Comorbidities

2025	PFIZER INC.: A Phase 2A, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Parallel Group, Dose-Ranging study of XXX-XX to assess Safety and Efficacy in Adult Participants with Obesity  

2024 	METSERA: A Phase 2B, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Dose-Ranging Study To Investigate The Safety And Efficacy Of Weekly And Monthly Regimens Of Coad ministered XXX And XXX In Adult Participants With Overweight Or Obesity

2024	AMGEN:   A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX in Adult Subjects with Type 2 Diabetes Mellitus  

  

2024	GASHERBRUM: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of XXXX in Participants Living with Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) with at Least One Weight-related Comorbidity  

  

2023	JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO: A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of XXX-XXX in Participants With Gout  

  

2022	PFIZER: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of XXXX, and Open-Label Oral XXXX, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately XXXX Compared to Matching Placebo in Adults with Obesity but Without T2DM.  

  

2021	ELI LILLY & COMPANY: A Phase 2 Study of Once-Weekly XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities.    

  

2021	ELI LILLY & COMPANY: A Phase 2 Study of Once-Daily XXXX Compared with Placebo and Once- Weekly XXXX in Participants with Type 2 Diabetes Mellitus      

  

2021	ELI LILLY & COMPANY: A Phase 2 Study of Once-Daily XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities.   

  

2021	PFIZER : A 26-Week, Phase 2B, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX Administration in Adults with Obesity     

  

  

  

Pain (Acute – Post Operative)  

  

2024	CALI BIOSCIENCES: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of XXXX in the Management of Postoperative Pain after Open Inguinal Herniorrhaphy.  

  

2024	VIATRIS: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Bunionectomy  

  

2024	VIATRIS: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Herniorrhaphy   

  

2023	VERTEX: A Phase 3, Randomize, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy 

  

2023	VERTEX: A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of XXXX for Acute Pain.     

  

2022	TEIKOKU PHARMA USA, INC.: A Double-Blind, Placebo-Controlled, Evaluation of the XXXX Transdermal Systems for Postoperative Analgesia Following Abdominoplasty      

  

2021	ACADIA PHARMACEUTICALS, INC.: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).     

  

2021	CALI PHARMACEUTICALS: A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX in the Management of Postoperative Pain After Open Inguinal Herniorrhaphy.   

  

2021	VERTEX PHARMACEUTICALS: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy.  

  

2020	VIVOZON, INC.: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy     

  

2019		HERON: A Phase 3b, Randomized, Open-Label Study of XXXXX as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy.   

  

   

  

2019 		TAIWAN TLC: entitled 'A Phase 2, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Efficacy o XXXXX for Postsurgical Pain Management Following Bunionectomy' ('Protocol') to be conducted at Institution ('Trial') to involve patients participating in the Trial ('Trial Subjects')     

  

   

  

2019		VERTEX: A Phase 2-4, Dose-Ranging Study to Evaluate Efficacy and Safety of XXXXX in Subjects With Acute Pain Following Bunionectomy.    

  

   

  

2019		VIVOZON: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy.    

  

   

  

2019		VIVOZON: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Abdominoplasty.    

  

  

  

Vaccine  

2025	PFIZER: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluatiing the Safety, Tolerability, Immunogencity and Efficacy of a Variant-Adapted XXX Vaccine in Healthy Participants 50 Through 64 Years of Age

2024	ICOSAVAX: A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of XXXX in Adults 60 Years of Age and older.  

  

2024	ICOSAVAX: A Phase 3, Global, Randomized, Modified Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of XXXX, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine, in adults 60 Years of Age and Older  

  

2023	MODERNA THERAPEUTICS: A Random, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of XXXX Administered as a Booster Dose Compared with XXXX in Participants Aged 12 Years and Older for the Prevention of COVID-19      

  

2022	PFIZER:  A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older     

  

2022	PFIZER : An Interventional, Randomized, Active-Controlled, Phase 2 Observer-Blind Study to Investigate the Safety, Tolerability, and Immunogenicity of a Bivalent XXXX RNA-Based Vaccine Candidate as a Booster Dose in Covid-19 Vaccine-Experienced Healthy Adults.	  

  

2021	JANSSEN : A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate XX Dose Levels of XXXX Administered as a Two-dose Schedule in Healthy Adults.   

  

   

  

2021	JANSSEN : A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of XXXX Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination with XXXX or XXXX.    

  

2021	PFIZER : A Phase 3, Randomized, Double-Blind Trial to Describe the Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine When Co-administered With A Booster Dose of XXXX in Adults 65 Years of Age and Older.   

  

2021	PFIZER : A Phase 3, Randomized, Observer-Blind Study To Evaluate The Safety, Tolerability And Immunogenicity Of A Lyophilized Formulation Of The Vaccine Candidate XXXX Against Covid-19 In Healthy Adults 18 Through 55 Years Of Age.    

  

2021	PFIZER : A Phase 3 Master Protocol To Evaluate Additional Dose(S) Of XXXX In Healthy Individuals Previously Vaccinated With XXXX.    

  

  

  

2020	JANSSEN : A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XXXX for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older     

  

2020	PFIZER: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of XXXX Vaccine Candidates Against COVID-19 in Healthy Adults.  

  

2019		PFIZER: A Phase 3, Randomized, Open-Label Trial to Evaluate The Safety 			and Immunogenicity of A 20-Valent Pneumococcal Conjugate Vaccine in Adults >= 		65 Years of Age with Prior Pneumococcal Vaccination.  

  

   

  

2019		PFIZER: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 - Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine - Naïve Adults 18 Years of Age and Older.     

  

   

  

2019		PFIZER: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-Valent Pneumococcal Conjugate Vaccine in 	Pneumococcal Vaccine - Naïve Adult 18 Through 49 Years of Age.    

  

   

  

2019		PFIZER: A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and 	Pharmacokinetics of XXXXX Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild or Moderate Chronic Plaque Psoriasis.    

  

   

  

2019		 PFIZER: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of XXXXX Administered Daily for 16 Weeks in Adults with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin.   

  

   

  

2019		 PFIZER: A Phase 2, Randomized, Double Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of XXXXX in Participants with Moderate to Severe Plaque Psoriasis.    

  

   

  

2019		TAKEDA: An Open-Label, Phase 3 Trial to Investigate the Immunogenicity 	and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(ies) for Dengue.    

  

  

  

Other Indication  

  

2024	METSERA: A Phase 2b, Multi-Center, Randomized, Placebo controlled Double-Blind Study to Investigate the Safety and Efficacy of 16 Weeks of Four Different Regimens of Once-Weekly XXXX in Participants with Obesity or Overweight  

  

2020	NOVAVAX, INC.: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a XXXX (XXXX) with XXXX Adjuvant in Adult Participants ≥ 18 years.      

  

2020	UPSHER-SMITH LABS: A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of XXXX on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy.  

  

2019		JANSSEN: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Study to  Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based 		Regimen in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory 	Tract Disease in Adults Aged 65 Years and Older.     

  

  

  

  

  

  

 

 